Jun 27 |
Cardiol Therapeutics Reports Results of 2024 Annual General and Special Meeting of Shareholders
|
Jun 25 |
Cardiol Therapeutics to Webcast Virtual Annual General and Special Meeting of Shareholders on June 26th at 4:30 p.m. EDT
|
Jun 17 |
Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients
|
Jun 13 |
Cardiol slips after mid-stage data for heart disease therapy
|
Jun 13 |
Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
|
Apr 2 |
Cardiol Therapeutics Announces Year-End 2023 Update on Operations
|
Feb 21 |
Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
|
Feb 15 |
Cardiol stock rallies 28% on FDA orphan drug status for CardiolRx
|
Feb 15 |
Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis
|
Jan 9 |
Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis
|